Last reviewed · How we verify
Sydney Centre for Reproductive Health Research — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| E2Nomac | E2Nomac | marketed | Selective Estrogen Receptor Modulator (SERM) | Estrogen receptor (ER-α/ER-β) | Reproductive Health / Gynecology |
Therapeutic area mix
- Reproductive Health / Gynecology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Eli Lilly and Company · 1 shared drug class
- Sebela Women's Health Inc. · 1 shared drug class
- Wyeth is now a wholly owned subsidiary of Pfizer · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Sydney Centre for Reproductive Health Research:
- Sydney Centre for Reproductive Health Research pipeline updates — RSS
- Sydney Centre for Reproductive Health Research pipeline updates — Atom
- Sydney Centre for Reproductive Health Research pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Sydney Centre for Reproductive Health Research — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sydney-centre-for-reproductive-health-research. Accessed 2026-05-18.